News

Seeking Alpha4d
Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone ...
In study Cohort B (N=80) of patients with BCG-unresponsive NMIBC papillary disease without CIS, ANKTIVA plus BCG demonstrated a 58.2% disease-free survival (DFS) rate at 12 months (primary ...
Medscape6d
Renal Papillary Calcification and the Development of Calcium Oxalate Monohydrate Papillary Renal Calculi
Background The objective of this study is to determine in a case series (four patients) how calcified deposits in renal papillae are associated with the development of calcium oxalate monohydrate ...
Stockhouse6d
Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC
First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumors, demonstrating the potential for bladder preservation with 94 percent of patients ...
Medscape6d
Long-term Follow up Results of Intraductal Papillary Mucinous Tumors of Pancreas
Background and Aim: Intraductal papillary mucinous tumor (IPMT) of the pancreas can be divided into three clinically distinct subtypes: main duct type, branch duct type and mixed type. Although it ...